Allgayer H - Search Results

1

Prognostic factors in gastric cancer.

Allgayer H, Heiss MM, Schildberg FW. Allgayer H, et al. Br J Surg. 1997 Dec;84(12):1651-64. Br J Surg. 1997. PMID: 9448610 Review.

2

Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM. Allgayer H, et al. Clin Exp Metastasis. 1998 Jan;16(1):62-73. doi: 10.1023/a:1006564002679. Clin Exp Metastasis. 1998. PMID: 9502078

3

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. Allgayer H, et al. J Clin Oncol. 2000 Jun;18(11):2201-9. doi: 10.1200/JCO.2000.18.11.2201. J Clin Oncol. 2000. PMID: 10829039

4

Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.

Allgayer H, Babic R, Beyer BC, Grützner KU, Tarabichi A, Schildberg FW, Heiss MM. Allgayer H, et al. Oncology. 1998 Mar-Apr;55(2):152-60. doi: 10.1159/000011850. Oncology. 1998. PMID: 9499190

5

Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery.

Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Ströhlein MA, Tarabichi A, Faist E, Jauch KW, Schildberg FW. Heiss MM, et al. Among authors: allgayer h. Shock. 1997 Dec;8(6):402-8. doi: 10.1097/00024382-199712000-00002. Shock. 1997. PMID: 9421852 Clinical Trial.

6

Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Heiss MM, et al. Among authors: allgayer h. Ann Surg. 1997 Dec;226(6):736-44; discussion 744-5. doi: 10.1097/00000658-199712000-00010. Ann Surg. 1997. PMID: 9409572 Free PMC article.

7

Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery.

Heiss MM, Fasol-Merten K, Allgayer H, Ströhlein MA, Tarabichi A, Wallner S, Eissner HI, Jauch KW, Schildberg FW. Heiss MM, et al. Among authors: allgayer h. Vox Sang. 1997;73(4):237-45. doi: 10.1046/j.1423-0410.1997.7340237.x. Vox Sang. 1997. PMID: 9407641 Clinical Trial.

8

Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients.

Heiss MM, Allgayer H, Gruetzner KU, Tarabichi A, Babic R, Mempel W, Jauch KW, Schildberg FW. Heiss MM, et al. Among authors: allgayer h. Anticancer Res. 1997 Jul-Aug;17(4A):2657-61. Anticancer Res. 1997. PMID: 9252697

9

An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Wilhelm Schildberg F, Heiss MM. Allgayer H, et al. Cancer. 1997 Jul 15;80(2):179-87. doi: 10.1002/(sici)1097-0142(19970715)80:2<179::aid-cncr2>3.0.co;2-p. Cancer. 1997. PMID: 9217027

10

Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.

Allgayer H, Heiss MM, Riesenberg R, Grützner KU, Tarabichi A, Babic R, Schildberg FW. Allgayer H, et al. Cancer Res. 1997 Apr 1;57(7):1394-9. Cancer Res. 1997. PMID: 9102229 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results